Published in Vaccine Weekly, September 20th, 2000
"CD22 is a B-cell specific antigen which is commonly expressed in indolent and aggressive NHL," stated John P. Leonard and colleagues from Weill Medical College of Cornell University and New York Presbyterian Hospital, and Immunomedics, Inc., and Garden State Cancer Center, New Jersey.
"Epratuzumab (Hll2 or LymphoCide), Immunomedics, Inc., Morris Plains, New Jersey) binds CD22, and in radiolabeled forms has been demonstrated to have...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly